NICE’s Report On The Feasibility Of Appraising The Use Of Bevacizumab (Avastin) To Treat Eye Conditions
NICE has published its findings after exploring the feasibility of advising the NHS on the clinical and cost effectiveness of bevacizumab (Avastin, Genentech/Roche) to treat wet age-related macular degeneration (AMD), the leading cause of blindness in the UK, and other conditions affecting the eye...